It is an exciting time in ovarian cancer medicine. In the past 2 years, three randomised trials have shown that antiangiogenic agents, which inhibit VEGF, improve outcomes in the disease. Two of these trials (ICON7 and GOG-218) questioned the value of adding the anti-VEGF antibody, bevacizumab, to first-line chemotherapy, whereas the third trial (OCEANS) assessed the benefit of adding this drug to cytotoxic agents in recurrent disease. All three studies showed a significant improvement in progression-free...